Health Canada has issued an alert after Gore identified, through quality‑control testing, that a subset of its VIABAHN® endoprosthesis devices were processed using equipment that was operating outside the validated range. This condition could potentially lead to an incorrect bonding location of the distal tip onto the delivery catheter.
Manufacturers and users are advised to review the affected product batches and follow any further guidance from Health Canada regarding corrective actions or product handling.
Cập nhật pháp chế4 thg 9, 2026•1 phút đọc
Gore VIABAHN® Device Quality Issue Identified
Gore discovered some VIABAHN® devices were processed on equipment outside validated range, risking incorrect distal tip bonding.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: Health Canada
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá